Objective: To assess the efficacy and tolerability of quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Methods: Multicenter randomized, double-blind, placebocontrolled parallel groups clinical trial involving 40 patients with dementia with Lewy bodies (n ϭ 23), Parkinson disease (PD) with dementia (n ϭ 9), or Alzheimer disease with parkinsonian features (n ϭ 8). The main outcome measure for efficacy was change in the Brief Psychiatric Rating Scale (BPRS) from baseline to 10 weeks of therapy. For tolerability it was change in the Unified PD Rating Scale (UPDRS) motor section over the same time period. The trial was confounded by the need for a design change and incomplete recruitment. Results: No significant differences in the primary or secondary outcome measures of efficacy were observed. An unexpectedly large placebo effect, inadequate dosage (mean 120 mg/day), and inadequate power may have contributed to lack of demonstrable benefit. Quetiapine was generally well-tolerated and did not worsen parkinsonism, but was associated with a trend toward a decline on a measure of daily functioning. Conclusions: Quetiapine was well-tolerated and did not worsen parkinsonism. Although conclusions about efficacy may be limited, the drug in the dosages used did not show demonstrable benefit for treating agitation or psychosis in patients with dementia and parkinsonism. These findings are in keeping with prior studies reporting limited efficacy of various medications for reducing behavioral problems in demented patients.
The optimal therapy of agitation and psychosis in demented patients with coexisting extrapyramidal, parkinsonian motor disturbances, which is characteristic of dementia with Lewy bodies (DLB) and Parkinson disease (PD) and is reported in up to half of patients with Alzheimer disease (AD), 1,2 poses a pharmacologic dilemma since neuroleptic antipsychotics are dopamine receptor antagonists and can worsen parkinsonism. Severe motor deterioration (neuroleptic sensitivity) has been described in some patients with DLB after exposure to antipsychotic drugs, making clinicians reluctant to prescribe these to patients with DLB. 3 Because of their lower risk of extrapyramidal motor disturbances, the newer atypical antipsychotics have been used to treat behavior problems in demented patients. [4] [5] [6] None of these studies, however, selected subjects for the presence of extrapyramidal features. Cholinesterase inhibitors used to treat cognitive disturbances in AD and DLB have also been reported to improve associated behavioral problems. 7, 8 A potential problem of tolerability in parkinsonian patients, however, was raised by observations that parkinsonism worsened in some treated subjects. 7 We designed a multicenter, randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and tolerability of the atypical antipsychotic quetiapine (selected due to its purported low risk of inducing or worsening extrapyramidal dysfunction 9 ) and the cholinesterase inhibitor donepezil, used alone or in combination (2 ϫ 2 factorial design), for the treatment of psychosis or agitation in patients with both dementia and parkinsonism. The study was initiated in September 2002 but encountered slow recruitment due to problems identifying potential subjects who were not receiving a cholinesterase inhibitor (such treatment was an exclusion criterion). It appeared that standard clinical practice had evolved so that most demented subjects (AD, DLB, and PD) were being treated with this class of medi-cation. In April 2003, after only nine subjects were enrolled, the study design was modified to a two-arm trial comparing quetiapine and placebo. Subjects were allowed to take a cholinesterase inhibitor during the trial. Of the nine subjects who participated in the original protocol, one was assigned to donepezil alone and four were assigned to donepezil plus quetiapine. Data for the subject assigned to donepezil alone were excluded from all analyses. We analyzed our results both including and excluding the four subjects assigned to donepezil plus quetiapine in the original protocol. All of the following information relates to the modified protocol.
METHODS
The primary aim of this study was to determine the efficacy of quetiapine for the treatment of psychosis or agitation in patients with dementia complicated by coexistent parkinsonism. The secondary aim was to determine the safety and tolerability of the drug in this population, particularly its influence on parkinsonism. Moreover, we examined whether patients with AD, DLB, and PD differed with respect to quetiapine-induced worsening of parkinsonism (i.e., neuroleptic sensitivity). We hypothesized that the drug would be effective and well-tolerated in all three conditions. Subjects. Eligible subjects included men or women of any ethnicity. Inclusion criteria were 1) fluent in English or Spanish, 2) age 50 years or older, 3) presence of dementia as defined in the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV), 10 4) meets National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association diagnostic criteria for probable AD 11 or Consortium diagnostic criteria for DLB 12 or UK Brain Bank criteria for PD, 13 5) presence of psychosis (as defined in Jeste and Finkel , 2000, 14 and the DSM-IV 10 ) or agitation (as defined in Cohen-Mansfield and Billig, 1986 15 ) (the duration of psychosis or agitation prior to enrollment was not recorded), 6) presence of extrapyramidal motor features (defined by having two or more of the following four signs: resting tremor, bradykinesia, limb rigidity, shuffling gait), 7) sum of ratings for the tremor at rest, rigidity (highest one of the four rigidity items), bradykinesia, and gait items of the Unified PD Rating Scale 16 greater than or equal to 2, 8) Brief Psychiatric Rating Scale (BPRS) 17 score greater than or equal to 12, 9) at least one of the following BPRS items scored greater than or equal to 3 (moderate): hostility, suspiciousness, hallucinatory behavior, uncooperativeness, unusual thought content, excitement, 10) presence of a caregiver/informant who is willing to accompany the subject to all evaluation visits and to report on the subject's activities and behavior, 11) on a stable dosage of non-excluded medications for at least 4 weeks, 12) in stable medical condition for at least 4 weeks, 13) physically acceptable for the study as confirmed by medical history, physical examination, and screening clinical laboratory tests (blood counts, serum chemistries, electrocardiogram), 14) able to ingest study medications (confirmed using placebo pills), and 15) supervision available for administration of study medications. Exclusion criteria were 1) Mini-Mental State Examination (MMSE) 18 score Ͻ8, 2) use of a classic or atypical antipsychotic drug in the prior 3 weeks, 3) a history of a severe adverse reaction to any atypical antipsychotic drug, 4) a serious medical illness that would preclude the safe administration of quetiapine, 5) known pregnancy, and 6) current evidence or history in the prior 2 years of epilepsy, focal brain lesions, head injury with loss of consciousness or immediate confusion after the injury. Patients thought to be experiencing a toxic, metabolic, or infectious encephalopathy (delirium) were excluded. Excluded concomitant medications included any classic or atypical antipsychotic, anxiolytic, or hypnotic drug. Subjects were allowed to take cholinesterase inhibitors, memantine, and antiparkinsonian drugs except anticholinergics and amantadine. Medication dosages had to be stable for at least 2 weeks prior to screening. Subjects could reside in their own residence or in a supervised care setting such as a nursing home. Subjects were enrolled, treated, and assessed at the 15 participating medical centers. All subjects were enrolled after the subject or caregiver provided informed consent.
Interventions. Subjects were begun on quetiapine (or matching placebo) at a dosage of 25 mg at bedtime. Based on frequent (no less than 1 per week) telephone discussions between the subject/caregiver and the site investigator, the dosage was titrated by a maximum of 25 mg every 2 days based on efficacy for target symptoms and tolerability up to a maximum dosage of 150 mg twice daily (morning, bedtime). Investigators were encouraged to advance the dosage to at least 100 mg/day if tolerated. Dosage could be reduced at any time to minimize side effects. The dosage was not increased to optimize efficacy during the last 2 weeks of the study so that the final evaluation reflected a stable medication regimen.
For any subject who experienced disabling psychosis or agitation that failed to adequately respond to study medications, rescue therapy with lorazepam up to 2 mg/day was permitted. Lorazepam use was not allowed in the 24-hour period prior to clinical evaluation so that any drug-induced sedation would not interfere with our assessments.
Outcomes. Subjects underwent identical clinical assessments just prior to beginning experimental therapy (baseline visit) and after 6 and 10 weeks of treatment. The BPRS 17 served as the primary outcome measure because extensive data on this scale were available from the PSYCLOPS Trial 19 and since they were used in our power calculations. The Neuropsychiatric Inventory (NPI) 20 was a secondary measure of psychosis and agitation. The MMSE 18 was a measure of cognitive function and the ADCS Clinical Global Impression of Change (ADCS-CGIC) 21 and the ADCS Activities of Daily Living Questionnaire 22 served as measures of overall treatment response. The Motor Examination component of the UPDRS 16 was our outcome measure for assessing the drug's influence on parkinsonism and the Rochester Movement Disorders Scale for Dementia (R-MDS-D) 23 served to help distinguish effects on parkinsonism from those on pseudo-parkinsonism (akinetic/rigid features). Other assessments of safety included supine and standing blood pressure and pulse, physical examination, EKG, blood count and chemistries, and systematic recording of any adverse events. Subject safety was monitored by an independent safety committee.
Sample size. Power analysis for the two-arm trial was based on a two-sided two-sample t test. The primary outcome measure for this study was the change in total BPRS from baseline to 10 weeks. Effect sizes used in the power analysis for the BPRS change scores were taken from a published controlled clinical trial of clozapine as treatment of psychosis in patients with PD (PSYCLOPS Trial). 19 In that trial, the mean BPRS change score for the placebo arm was Ϫ2.6 Ϯ 6.9 (Ϯ SD) while the mean change for the treatment arm was Ϫ9.3 Ϯ 7.8. Power analysis assumed a common SD of 7.4. A secondary measure of overall response was the ADCS-CGIC. In the PSYCLOPS trial, changes of Ϫ0.5 Ϯ 1.0 and Ϫ1.6 Ϯ 1.5 for placebo and clozapine treatment groups were reported. Power analysis for ADC-CGIC assumed a common SD of 1.3. A sample size of 25 subjects in each treatment group provided a power of 81.7% for the BPRS and 76.3% for the ADC-CGIC, assuming an attrition rate of 15% and a type I error rate of 5%. Data from the PSY-CLOPS Trial were used since at the time this study was planned there were no adequate data involving studies of quetiapine or controlled trials of atypical antipsychotics in other demented populations.
Randomization. Patients were randomly allocated using a permuted block design stratified by study site with equal probability of being assigned to the treatment arm or placebo.
Blinding. Study participants, investigators administering study medications, and those assessing the outcomes were blinded to group assignment. No formal assessment of the success of blinding was carried out.
Statistical analysis. The primary outcome measure was the 10-week change score in the total BPRS. The primary analysis was by intention-to-treat (ITT) in which all randomized subjects with at least 1 post-baseline visit were included. An analysis of covariance (ANCOVA) was used to compare the 10-week change in total BPRS between the quetiapine and placebo groups, using the baseline score as a covariate. All baseline variables were assessed as potential confounders. Those variables found significantly associated with treatment group (p Ͻ 0.1) and outcome (p Ͻ 0.15) were included as covariates in the ANCOVA model. For participants who discontinued from the study or had missing data at 10 weeks, data were imputed by using the last observation carried forward (LOCF) approach. As a confirmatory analysis, the generalized estimating equations (GEE) approach using a compound symmetry structure for the working correlation matrix was used to assess group differences in the rate of change of total BPRS.
Ordinal logistic regression analysis was used to compare the 10-week ADCS-CGIC scores between the quetiapine and pla-cebo groups with appropriate checks for the proportional odds assumption. The protocol initially proposed to treat the ADCS-CGIC as a continuous measure. However, since 73% of the patients had a 10-week ADCS-CGIC score of 3, 4, or 5, the CGIC score was treated as an ordinal measure. All other secondary outcomes (NPI, UPDRS motor, MMSE, ADCS-ADL, and the R-MDS-D) were continuous and hence were analyzed by ANCOVA models as described above for the BPRS. Holm's method was used to adjust for the multiple outcomes.
In addition to an ITT analysis, a completers and compliers analysis was performed with compliance obtained from pill counts. Completers were defined as patients with a 10-week visit while compliers were defined as completers who were at least 80% compliant with study medication.
The proportion of subjects with adverse events in the two treatment groups were compared using Fisher exact test. Tenweek change in vital signs and laboratory measures between the treatment groups were compared using ANCOVA as described for the BPRS. All analyses were run in R 2.1.1 (www.R-project.org). No protocol deviations occurred. Of the 57 patients who were screened for this trial, a total of 40 subjects (the one patient randomized to donepezil alone was excluded from the analysis) were eligible and were randomized (20 patients were assigned quetiapine and 20 patients were assigned placebo). Completion rates were 65% for the placebo group and 85% for the quetiapine group. The most frequent reasons for study discontinuation were concern over placebo (one in each treatment group), effectiveness of medication (two in the placebo arm, one in the quetiapine arm), and adverse effects (three in the placebo arm, one in the quetiapine arm) experienced. Of the 40 randomized subjects, 4 did not have a post-baseline visit and were not included in the ITT analysis.
RESULTS
Baseline data. Baseline demographic and clinical characteristics of participants in each treatment group are summarized in table 1. Subjects in the two groups were well-balanced with no significant differences in their main demographic and clinical characteristics. More subjects assigned to placebo (n ϭ 14) were taking a cholinesterase inhibitor than those assigned to quetiapine (n ϭ 9). The cholinesterase inhibitors taken were donepezil (n ϭ 16), galantamine (n ϭ 4), and rivastigmine (n ϭ 3). Eight subjects assigned to placebo and seven assigned to quetiapine were being treated with a dopaminergic antiparkinsonian medication. Only one subject (assigned to placebo) had been treated with an antipsychotic drug in the 3 months prior to enrollment.
Outcomes and estimation. Study results for the ITT analyses are summarized in table 2. There were no significant differences in primary or secondary outcome measures after 10 weeks of treatment between the two treatment groups. Results from the ITT and the completers analyses revealed similar results. The analysis of covariance model showed no difference on the mean change in the total BPRS in the ITT analysis (95% CI for difference in change scores: Ϫ7.1, 2.7; p ϭ 0.38) and completers analysis (95% CI for difference in change scores: Ϫ6.4, 4.1; p ϭ 0.66). Confirmatory analysis using the GEE approach also showed no differences in the rate of change in total BPRS between the two treatment groups (p ϭ 0.49). Based on BPRS there was no significant difference in response to placebo among diagnostic groups (AD, DLB, PD), although the sample sizes are small.
There was no difference in the final ADCS-CGIC score between treatment and placebo group in the ITT and completers analysis (p ϭ 0.53 ITT and p ϭ 0.13). The assumption of proportional odds was met for the final ADCS-CGIC model. Similarly, there were no significant differences between the quetiapine and placebo groups in any of the other secondary outcome measures. GEE analysis also confirmed these results. We found no statistical evidence that concurrent treatment with a cholinesterase inhibitor influenced our outcomes. No material changes in outcomes were found when data for the four subjects assigned to donepezil plus quetiapine in the original protocol were removed.
The overall mean compliance rate was 100% Ϯ 10% with no difference in compliance rates or in the proportion of compliers between the two treatment groups. Compliers analyses of the primary and secondary outcomes showed results consistent with the ITT and completers analyses.
Safety and tolerability. Treatment-emergent adverse events (AE) observed in the treatment groups are summarized in table 3 by system organ class. There were no discontinuations in this study due to AEs in either of the two treatment groups (figure). At least one AE was reported in 65% of subjects taking quetiapine and 45% of subjects taking placebo, but the rates were similar between groups (p ϭ 0.34). There were no differences between the groups in the rate of AE by system organ class except for a slight increase in nervous system events in the quetiapine group. For the nervous system events, the main difference between treatment groups was that more quetiapine-treated subjects developed lightheadedness (n ϭ seven events in five patients) than those receiving placebo (n ϭ one event in one patient). Most of the adverse events were non-serious and judged to be unrelated to the treatment. DISCUSSION Our primary outcome measure of behavioral problems (BPRS) improved in both treatment groups but the difference between quetiapine and placebo was not significant. We were thus unable to detect a pharmacologic effect of the drug in treating agitation or psychosis. In the PSYCLOPS Trial of clozapine in patients with PD and druginduced psychosis, 19 which was used to carry out our power calculations, clozapine produced a mean 9.3 point improvement in BPRS score, which is similar to the mean 8.2 point improvement during quetiapine therapy in our study. On the other hand, the improvement in the placebo group in the two studies differed, being a mean of 2.6 points in PSY-CLOPS and 6.2 points in this trial. Our observed magnitude of change with placebo was unexpected and may explain the lack of observed significant benefit of quetiapine. On the other hand, the clinical effect of the agent on psychiatric symptoms in our studied population may indeed be minor. This conclusion is supported by the absence of significant treatment effects on our secondary behavioral outcome measures, the NPI and the CGIC. Our results are compatible with a recent study that failed to show superiority of the atypical antipsychotic risperidone for the treatment of psychosis in patients with AD 24 and a recent literature review that concluded pharmacologic therapies are not particularly effective for the management of neuropsychiatric symptoms of dementia and pointed out that the effects of atypical antipsychotics are modest. 25 It is possible that our sample size was insufficient to detect significant treatment effects of quetiapine compared to placebo and we did not have insufficient power to determine if treatment effect differed across diagnostic groups (AD, DLB, PD). The reason for a larger placebo effect in our study compared to the PSYCLOPS trial is unclear. The primary difference in study designs was inclusion of a wider variety of diagnoses in our study, AD and DLB in addition to PD. In addition, all subjects in our study had dementia, while this was not a required condition in PSYCLOPS. It is possible that clinical effects of antipsychotic medications may be more difficult to detect in demented subjects, per-haps because their behavioral disturbances are more heterogeneous than the drug-induced psychosis studied in PSYCLOPS. A substantial placebo effect has been seen in other trials of medications to treat behavioral problems in demented patients and has been attributed to regression to the mean. 26 More subjects assigned to placebo were taking a cholinesterase inhibitor. Since the optimal clinical benefits of these drugs might be delayed, it is possible that subjects who recently started their drug (a stable dosage for at least 2 weeks was required for entry) experienced some increasing clinical benefit while participating in the trial. This might explain the larger than expected placebo effects. However, we found no statistical evidence that use of a cholinesterase drug influenced our results. The four subjects assigned to donepezil plus quetiapine in the original protocol had new exposure to cholinesterase inhibitor therapy during the trial, but we found no significant difference in our findings when these subjects were excluded from analysis. Values are means (SD) of unadjusted scores at baseline and at last visit. Imputation method was the last observation carried forward (LOCF). *Four patients were excluded from the analysis since they did not have a post-baseline measurement. †The estimate and 95% CI for ADCS-CGIC reflect ORs from the ordinal logistic regression analysis. All other estimates reflect results from the final analysis of covariance model. Subjects in our trial had lower BPRS scores at baseline than those in PSYCLOPS (placebo group: 27.2 Ϯ 8.7 vs 40.6 Ϯ 12.1; drug group: 26.8 Ϯ 8.8 vs 38.6 Ϯ 12.1) and it may be more difficult to detect treatment effects in our more mildly affected cohort. Interestingly, active treatment produced a 24% change in BPRS in the PSYCLOPS Trial and a larger change of 31% in our study. The main difference in results relates to the larger placebo effect in our trial.
Another possible explanation for the absence of observed benefit of quetiapine in our study is the use of inadequate dosages. Our mean dosage of the drug was 120 mg/day, while some have suggested that dosages of 200 mg/day or higher are needed to control agitation in demented patients. 27 Quetiapine produced no significant increase in parkinsonism as assessed by the UPDRS and the R-MDS-D. This was true across all three diagnoses, AD, PD, and DLB. These results suggest that at least some atypical antipsychotics can be used safely, without worsening motor features, in demented patients with coexisting parkinsonism. DLB subjects showed no evidence of drug sensitivity to quetiapine. Our findings are in agreement with other preliminary reports that the atypical antipsychotics clozapine and quetiapine are well tolerated in DLB patients, 28 although we have small sample sizes in each of the diagnosis groups. Our study may have been underpowered to detect other adverse effects of therapy.
Quetiapine-treated subjects experienced a trend toward a greater worsening of functional abilities compared to those receiving placebo as measured by the ADL Scale. The cause of functional decline is unclear, but it might be related to the observed side effect of lightheadedness. A recent study suggested that quetiapine may cause a substantial decline in MMSE scores when administered to patients with dementia. 29 This effect was not observed in the current study.
Although our study indicates that short-term use of quetiapine does not significantly worsen parkinsonism or cognition in treated subjects, a clinical benefit over placebo was not observed. The drug was also associated with a trend toward a greater decline in overall function compared to placebo. These results, combined with recent concerns about an increased risk of death in elderly patients treated with antipsychotic drugs (atypical and conventional), 30 suggest that quetiapine may not be the best first-line treatment approach for agitation or psychosis in demented patients. Behavioral interventions have shown some success with an effect size equivalent to medications. 31 Other medications, such as antiepileptic mood-stabilizing drugs and anxiolytics, have had reported benefit for behav- Several subjects reported more than one AE. p Values for the comparisons were obtained using Fisher exact test. Rates of events were compared only for categories of system/organ classes containing at least five patients overall. There were no significant differences between the two treatment groups in the mean 10-week change in vital signs or laboratory values.
ioral problems in demented patients but generally with only modest effects. Although we were unable to formally test cholinesterase inhibitors in randomized fashion as originally planned, this drug class has shown at least preliminary evidence of efficacy for behavioral problems in the setting of dementia, 7, 8 although the effect size has been small and the clinical response may be slow. 25 More definitive data on the value of cholinesterase inhibitors for psychiatric symptoms in demented patients are needed. A recent trial of rivastigmine in demented patients with PD indicated that this cholinesterase inhibitor was reasonably tolerated. 32 A recent review article concluded that data are only preliminary but suggested that cholinesterase inhibitors may be efficacious and well-tolerated by patients with DLB. 33 Although we had hoped to investigate this, we could not recruit sufficient subjects to compare the effects of a cholinesterase inhibitor to those of an antipsychotic drug in demented and parkinsonian patients.
At present, there is a lack of effective and welltolerated therapies for the control of agitation and psychosis in patients with dementia.
